Reminder of Zoetis Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements during the class period, claiming strong market share and sales growth, while in reality, the adoption of its key products was sharply declining, resulting in investor losses.
- Market Share Decline: Zoetis' Simparica Trio has lost significant market share to a lower-priced competing product with broader indications, indicating a slowdown in the overall market, which could impact future revenues.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and expertise, prompting investors to carefully select their legal counsel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 82.200
Low
130.00
Averages
154.20
High
200.00
Current: 82.200
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Market Share Decline: The lawsuit alleges that Zoetis' veterinarian prescription growth and market share for flagship products have significantly weakened due to FDA safety warnings, resulting in investor losses when the true situation became known.
- Law Firm Credentials: Rosen Law Firm is recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements during the class period, claiming strong market share and sales growth, while in reality, the adoption of its key products was sharply declining, resulting in investor losses.
- Market Share Decline: Zoetis' Simparica Trio has lost significant market share to a lower-priced competing product with broader indications, indicating a slowdown in the overall market, which could impact future revenues.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and expertise, prompting investors to carefully select their legal counsel.
See More
Zoetis Faces Class Action Lawsuit Allegations
- Lawsuit Background: Zoetis Inc. is facing a class action lawsuit from the City of Ann Arbor Retiree Health Care Benefit Plan, alleging violations of the Securities Exchange Act of 1934 for securities transactions between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for investors to apply as lead plaintiffs.
- Market Performance Decline: The lawsuit claims that Zoetis' flagship products, including Librela and Simparica Trio, have experienced significant market share losses, particularly after FDA safety warnings led to a sharp decline in veterinarian prescriptions for Librela, causing the stock price to drop nearly 14% in November 2025.
- Financial Results Disclosure: On February 12, 2026, Zoetis reported its fourth quarter and full year 2025 financial results, revealing weakening demand trends and increasing competitive pressures in its animal health portfolio, which contributed to further stock price declines.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Zoetis securities during the class period can seek appointment as lead plaintiff, representing the interests of other investors, highlighting the lawsuit's potential impact on stakeholders.
See More
Zoetis Investors Advised of Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm advises Zoetis investors of a class action lawsuit for those who purchased securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Declining Financial Performance: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7 per share, indicating a more challenging operating environment than previously anticipated.
- Severe Market Reaction: Following the earnings report on May 7, 2026, Zoetis's stock price plummeted by $23.91, or 21.5%, closing at $87.31 per share, reflecting investor concerns over the company's future performance and a reassessment of its profitability.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy to discuss options for recovering losses, demonstrating the firm's commitment to supporting investor rights.
See More
Zoetis Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Zoetis, alleging securities fraud and unlawful business practices by the company and certain executives, with investors needing to apply as Lead Plaintiffs by July 27, 2026, highlighting serious governance concerns.
- Disappointing Earnings: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7.00 per share, indicating a more challenging operating environment than anticipated, which could undermine investor confidence.
- Stock Price Plunge: Following the earnings release, Zoetis's stock price fell by $23.91, or 21.5%, closing at $87.31 per share, reflecting a pessimistic market outlook on the company's future prospects, potentially leading to further investor sell-offs.
- Market Reaction Insight: CEO Kristin Peck noted increased price sensitivity among pet owners, resulting in fewer veterinary visits and weaker demand, suggesting the company's inadequate market adaptability in the current economic climate, which may impact long-term growth potential.
See More
Zoetis Faces Class Action Lawsuit Over Misleading Statements
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Loss of Market Share: Zoetis's Trio product lost market share, while its Apoquel and Cytopoint dermatology products were adversely affected by the introduction of new competing treatments, contributing to the characterization of the company's public statements as false and materially misleading.
- Investor Damages: As the market learned the true situation regarding Zoetis, investors suffered significant damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover their losses.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Market Share Decline: The lawsuit alleges that Zoetis' veterinarian prescription growth and market share for flagship products have significantly weakened due to FDA safety warnings, resulting in investor losses when the true situation became known.
- Law Firm Credentials: Rosen Law Firm is recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements during the class period, claiming strong market share and sales growth, while in reality, the adoption of its key products was sharply declining, resulting in investor losses.
- Market Share Decline: Zoetis' Simparica Trio has lost significant market share to a lower-priced competing product with broader indications, indicating a slowdown in the overall market, which could impact future revenues.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and expertise, prompting investors to carefully select their legal counsel.
See More
Zoetis Faces Class Action Lawsuit Allegations
- Lawsuit Background: Zoetis Inc. is facing a class action lawsuit from the City of Ann Arbor Retiree Health Care Benefit Plan, alleging violations of the Securities Exchange Act of 1934 for securities transactions between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for investors to apply as lead plaintiffs.
- Market Performance Decline: The lawsuit claims that Zoetis' flagship products, including Librela and Simparica Trio, have experienced significant market share losses, particularly after FDA safety warnings led to a sharp decline in veterinarian prescriptions for Librela, causing the stock price to drop nearly 14% in November 2025.
- Financial Results Disclosure: On February 12, 2026, Zoetis reported its fourth quarter and full year 2025 financial results, revealing weakening demand trends and increasing competitive pressures in its animal health portfolio, which contributed to further stock price declines.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Zoetis securities during the class period can seek appointment as lead plaintiff, representing the interests of other investors, highlighting the lawsuit's potential impact on stakeholders.
See More
Zoetis Investors Advised of Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm advises Zoetis investors of a class action lawsuit for those who purchased securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Declining Financial Performance: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7 per share, indicating a more challenging operating environment than previously anticipated.
- Severe Market Reaction: Following the earnings report on May 7, 2026, Zoetis's stock price plummeted by $23.91, or 21.5%, closing at $87.31 per share, reflecting investor concerns over the company's future performance and a reassessment of its profitability.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy to discuss options for recovering losses, demonstrating the firm's commitment to supporting investor rights.
See More
Zoetis Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Zoetis, alleging securities fraud and unlawful business practices by the company and certain executives, with investors needing to apply as Lead Plaintiffs by July 27, 2026, highlighting serious governance concerns.
- Disappointing Earnings: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7.00 per share, indicating a more challenging operating environment than anticipated, which could undermine investor confidence.
- Stock Price Plunge: Following the earnings release, Zoetis's stock price fell by $23.91, or 21.5%, closing at $87.31 per share, reflecting a pessimistic market outlook on the company's future prospects, potentially leading to further investor sell-offs.
- Market Reaction Insight: CEO Kristin Peck noted increased price sensitivity among pet owners, resulting in fewer veterinary visits and weaker demand, suggesting the company's inadequate market adaptability in the current economic climate, which may impact long-term growth potential.
See More
Zoetis Faces Class Action Lawsuit Over Misleading Statements
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Loss of Market Share: Zoetis's Trio product lost market share, while its Apoquel and Cytopoint dermatology products were adversely affected by the introduction of new competing treatments, contributing to the characterization of the company's public statements as false and materially misleading.
- Investor Damages: As the market learned the true situation regarding Zoetis, investors suffered significant damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover their losses.
See More
